CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| REVENUES: | ||||
| Total revenues | $ 476,784 | $ 461,097 | $ 1,408,338 | $ 1,249,605 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 188,793 | 96,949 | 398,134 | 263,567 |
| Research and development | 147,053 | 172,963 | 471,449 | 542,195 |
| Selling, general and administrative | 179,450 | 170,112 | 542,157 | 493,024 |
| Intangible asset amortization and contingent consideration | 17,429 | 17,063 | 48,018 | 57,114 |
| Gain on sale of nonfinancial assets | 0 | 0 | (59,495) | (15,000) |
| Total operating expenses | 532,725 | 457,087 | 1,400,263 | 1,340,900 |
| INCOME (LOSS) FROM OPERATIONS | (55,941) | 4,010 | 8,075 | (91,295) |
| Equity in the loss of BioMarin/Genzyme LLC | (921) | (551) | (1,077) | (780) |
| Interest income | 4,004 | 5,340 | 13,539 | 17,537 |
| Interest expense | (9,597) | (2,937) | (24,560) | (16,530) |
| Other income, net | 1,239 | 3,960 | 1,886 | 6,038 |
| INCOME (LOSS) BEFORE INCOME TAXES | (61,216) | 9,822 | (2,137) | (85,030) |
| Benefit from income taxes | (846,019) | (45,214) | (839,138) | (46,158) |
| NET INCOME (LOSS) | $ 784,803 | $ 55,036 | $ 837,001 | $ (38,872) |
| NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) | $ 4.33 | $ 0.31 | $ 4.63 | $ (0.22) |
| NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) | $ 4.01 | $ 0.30 | $ 4.39 | $ (0.22) |
| Weighted average common shares outstanding, basic (in shares) | 181,142 | 179,289 | 180,592 | 178,873 |
| Weighted average common shares outstanding, diluted (in shares) | 197,674 | 185,924 | 194,959 | 178,873 |
| COMPREHENSIVE INCOME (LOSS) | $ 765,138 | $ 74,600 | $ 827,222 | $ (7,140) |
| Net product revenues | ||||
| REVENUES: | ||||
| Total revenues | 460,741 | 450,900 | 1,368,816 | 1,224,458 |
| Royalty and other revenues | ||||
| REVENUES: | ||||
| Total revenues | $ 16,043 | $ 10,197 | $ 39,522 | $ 25,147 |
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|